Kevin C. Tang Purchases 2,971,682 Shares of La Jolla Pharmaceutical (NASDAQ:LJPC) Stock
La Jolla Pharmaceutical (NASDAQ:LJPC) Director Kevin C. Tang bought 2,971,682 shares of the business’s stock in a transaction on Monday, January 13th. The stock was bought at an average cost of $7.00 per share, with a total value of $20,801,774.00.
NASDAQ LJPC traded up $1.00 during trading hours on Monday, hitting $7.00. 3,633,490 shares of the company’s stock traded hands, compared to its average volume of 1,680,728. The business’s fifty day moving average price is $3.78 and its two-hundred day moving average price is $7.50. The firm has a market capitalization of $190.10 million, a P/E ratio of -0.89 and a beta of 2.05. La Jolla Pharmaceutical has a 52 week low of $2.30 and a 52 week high of $13.90.
La Jolla Pharmaceutical (NASDAQ:LJPC) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.03). La Jolla Pharmaceutical had a negative return on equity of 715.11% and a negative net margin of 683.88%. The business had revenue of $5.71 million during the quarter, compared to the consensus estimate of $6.96 million. As a group, equities analysts predict that La Jolla Pharmaceutical will post -4.39 earnings per share for the current fiscal year.
LJPC has been the topic of several research analyst reports. ValuEngine cut La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday. SunTrust Banks lowered La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a report on Monday, November 25th. HC Wainwright cut La Jolla Pharmaceutical from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 26th. Finally, BidaskClub downgraded La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a report on Friday, September 27th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $14.17.
About La Jolla Pharmaceutical
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.
Recommended Story: Is it Safe to Invest in Commodities?
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.